STOCKS TELEGRAPH

Tag: Jaguar Health

  • 3 Stocks to Keep on Your Radar: Cardiol Therapeutics (CRDL), Dyadic International (DYAI), Jaguar Health (JAGX)

    3 Stocks to Keep on Your Radar: Cardiol Therapeutics (CRDL), Dyadic International (DYAI), Jaguar Health (JAGX)

    The biotechnology sector continues to demonstrate a strong link between clinical advancement and investor sentiment, with late-stage programs often serving as primary catalysts for valuation shifts. As therapies move closer to regulatory review, market focus intensifies on data integrity, study completion timelines, and the strength of underlying clinical endpoints.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is reinforcing its long-term investment profile through disciplined financial management, focused clinical execution, and a strategy aimed at maximizing future commercialization opportunities. As development-stage biotech companies navigate increasingly competitive capital markets, operational stability remains an important differentiator for investors.

    Market Momentum

    As of May 11, 2026, CRDL closed at $1.3350, up 1.14%, with trading volume of 370,080 shares versus an average volume of 686,413 shares. The company currently maintains a market capitalization of $149.093M and a beta of 0.43, reflecting relatively moderate volatility compared to many small-cap biotech peers. Shares continue to trade within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.38 implies significant upside potential if upcoming milestones are achieved.

    Financial and Operational Positioning

    Cardiol has previously indicated that its cash resources are expected to support operations into 2027, providing the company with flexibility to continue advancing the Phase III MAVERIC trial while supporting broader pipeline development activities. A stable funding runway may reduce near-term financing pressure and allow management to remain focused on clinical execution.

    Commercial Strategy

    Management has also emphasized a partnership-oriented approach for future commercialization efforts. This strategy could enable Cardiol to leverage the resources, regulatory expertise, and global infrastructure of larger pharmaceutical companies while maintaining focus on clinical innovation within inflammatory cardiovascular disease.

    Outlook

    With ongoing clinical progress, disciplined operational management, and a pragmatic commercialization strategy, Cardiol appears increasingly well-positioned to pursue long-term value creation as it advances toward future regulatory and partnership milestones.

    Dyadic International Inc, DE (DYAI)

    Dyadic International Inc, DE (NASDAQ: DYAI) started the day on May 11, 2026, with a price decrease of -5.52% at $0.72. During the day, the stock rose to $0.79 and sank to $0.70. Taking a long-term approach, DYAI posted a 52-week range of $0.65-$1.35.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 7.84%. Meanwhile, its Annual Earnings per share during the time was 7.84%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 60.87%. This publicly-traded company’s shares outstanding now amount to $36.19 million, simultaneously with a float of $27.08 million. The organization now has a market capitalization of $26.39 million.

    Jaguar Health Inc (JAGX)

    As of May 11, 2026, Jaguar Health Inc (NASDAQ: JAGX) got off with the flyer as it spiked 10.00% to $3.3. During the day, the stock rose to $3.45 and sank to $2.87. Taking a more long-term approach, JAGX posted a 52-week range of $2.53-$327.60.

    In the past 5-year timespan, the Healthcare sector firm’s annual sales growth was 85.33%. Meanwhile, its Annual Earnings per share during the time was 85.33%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 99.51%. This publicly-traded company’s shares outstanding now amount to $0.40 million, simultaneously with a float of $0.28 million. The organization now has a market capitalization of $1.32 million.

  • Jaguar Health (JAGX) Stock Regains Ground In After-Hour Session

    Jaguar Health (JAGX) Stock Regains Ground In After-Hour Session

    After-hours trading on Wednesday saw a big recovery in Jaguar Health, Inc. (NASDAQ: JAGX) shares, which rose 8.33% to $3.01. The shares ended the trading day at $2.78, somewhat offsetting the company’s previous 14.06% regular-session drop. The recovery followed a virtual presentation at the Emerging Growth Conference by Lisa Conte, the founder and CEO of Jaguar Health, outlining the company’s recent accomplishments and future objectives.

    Advancing Canalevia-CA1 in Veterinary Medicine

    Recently, a field research was started by Jaguar Health’s Jaguar Animal Health subsidiary for Canalevia-CA1, an FDA-conditionally authorized medicine for canine chemotherapy-induced diarrhea (CID). This prospective, randomized, open-label clinical research, which involves dogs receiving chemotherapy across the United States, has seen the establishment of the company’s first study site. The research compares the results of the treatment and control groups in order to gather empirical data in favor of complete FDA clearance.

    Enhanced Indications and Strategic Objectives

    Securing complete FDA clearance for the CID indication and expanding its usage to treat general, non-infectious diarrhea in dogs are the two primary goals Jaguar Health is pursuing with Canalevia-CA1 (crofelemer delayed-release tablets). Discussions are underway with potential partners to support the development and global commercialization of crofelemer for this broader indication.

    This strategic expansion reflects the company’s recognition of a significant unmet need in veterinary medicine. Jaguar Health estimates approximately six million annual cases of acute and chronic canine diarrhea are seen by U.S. veterinarians, marking a considerable market opportunity.

    Regulatory Progress and Development Focus

    Jaguar Health has opened a new Investigational New Animal Drug (INAD) filing with the FDA’s Center for Veterinary Medicine to investigate the possibility of using crofelemer to treat dogs’ general, non-infectious diarrhea in order to assist these efforts. As a major driver of its continuous business growth activities, the firm has determined that establishing a strategic alliance for this program is a top goal for 2025.

  • Jaguar Health (JAGX) Stock Rebounds After Announcing Cancer Care Expansion

    Jaguar Health (JAGX) Stock Rebounds After Announcing Cancer Care Expansion

    Last Friday during the after-market session, there was a noticeable increase in the shares of Jaguar Health, Inc. (NASDAQ: JAGX) following the announcement of a noteworthy commercial endeavor. After a normal session fall of -9.75% that left the shares at $4.63, the stock had a comeback of 6.914% after hours, finishing at $4.95.

    Increasing Business Activity

    Jaguar Health (JAGX) shared intention to expand its commercial operations in its main area of expertise, cancer supportive care. Part of that plan, JAGX will present at the American Society of Clinical Oncology (ASCO) Annual Meeting, which runs from May 31 to June 4. During the event, JAGX-division Napo Pharmaceuticals will have Gelclair on display at a booth. Jaguar Health recently obtained the in-license to sell Gelclair, a prescription drug authorized by the FDA for treating oral mucositis. The commercial launch of Gelclair is scheduled to commence in the third quarter of 2024 by Jaguar Health.

    Addressing Cancer Patients Issues

    JAGX’s Gelclair is a barrier-forming protective gel that coats the oral mucosa to assist control and lessen pain. It is used to treat sores in the mouth brought on by a number of illnesses, including oral mucositis and stomatitis. Gelclair does not hurt or function as a numbing agent like other treatments.

    Oral mucositis has a substantial financial impact; extra expenses for each patient with head and neck cancer surpass $17,000. With its handy, user-friendly, and clinically proven approach, Gelclair delivers patients quick and durable pain relief that enhances their ability to swallow, eat, drink, speak, and sleep.  It also reduces the necessity for parenteral feeding and opiate analgesics.

    Expanding Focus On Cancer Supportive Care

    At the ASCO Annual Meeting, Jaguar Health will promote awareness among oncologists about Gelclair and the company’s growing commitment to cancer supportive care. This commitment is further underscored by Jaguar Health’s five-year dedication to studying the prevention of cancer therapy-related diarrhea through the phase 3 OnTarget trial. This trial focuses on over 24 targeted cancer agents that have an incidence of more than 50% diarrhea, with top-line results expected soon.

  • Jaguar Health Faces Steep Decline Amid Upcoming Reverse Stock Split

    Jaguar Health, Inc. (NASDAQ: JAGX) experienced a tumultuous trading session on Friday, witnessing a nearly 10% drop from $0.29 to $0.26. The situation worsened over the weekend, and by Monday’s premarket hours, the stock had plunged further to the $0.18 zone, reflecting a significant loss in investor confidence.

    Stock Performance and Volume Surge

    The substantial decline in Jaguar Health’s stock price was accompanied by an unprecedented surge in trading volume, with nearly 58 million shares changing hands. This volume spike was primarily driven by sellers offloading their shares, exacerbating the downward pressure on the stock.

    The sharp drop reflects market apprehension surrounding the company’s financial health and upcoming corporate actions.

    Company Overview and Reverse Stock Split

    Jaguar Health is a commercial-stage pharmaceuticals company engaged in developing gastrointestinal products, operating through Human Health and Animal Health segments.

    Its Human Health segment focuses on Mytesi, a product for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment deals with both prescription and non-prescription products for companion and production animals.

    A critical factor contributing to the recent stock performance is Jaguar Health’s history of significant share dilution. From 2022 to 2023, the number of outstanding shares skyrocketed from 2 million to 73 million.

    In an effort to address these concerns and comply with Nasdaq’s listing standards, Jaguar Health will implement a one-for-sixty reverse stock split on Thursday, May 23, 2024. This move aims to consolidate shares, reduce outstanding share counts, and make the stock more attractive to institutional investors.

    Conclusion

    As Jaguar Health braces for its reverse stock split, investors remain cautious. The split, approved at a Special Meeting of Stockholders, will see every sixty shares reclassified into one share without changing the par value. The company hopes this strategic move will bolster compliance with Nasdaq’s standards and restore investor confidence. Stockholders will receive instructions from Equiniti Trust Company, LLC on how to exchange their certificates post-split.

  • Jaguar Health (JAGX) Pre-market Surge Continues: Eyes on Elite Ped-GI Congress

    In an unprecedented move, Jaguar Health, Inc. (NASDAQ: JAGX) sustained its remarkable momentum from Thursday, catapulting another 21% in premarket trading on Friday. Investors are witnessing an astonishing rally, with signs pointing towards further gains throughout the day.

    This surge comes amidst a lack of immediate news catalysts, fueling speculation of a potential profit-taking dip in the near future. However, for now, bullish sentiment prevails, propelling JAGX to new heights.

    Company Profile and Recent Developments

    Jaguar Health, Inc. operates as a commercial-stage pharmaceuticals company, specializing in gastrointestinal products. Its Human Health segment focuses on manufacturing and promoting Mytesi, offering relief for non-infectious diarrhea in adults with HIV/AIDS.

    Meanwhile, the Animal Health segment is dedicated to providing prescription and non-prescription products for companion and production animals.

    This week, the company announced its sponsorship of the 10th Annual Elite Ped-GI Congress in Abu Dhabi, UAE, through its subsidiary, Napo Pharmaceuticals. The congress features a panel discussion, “Masterclass in Congenital Diarrhea,” spotlighting microvillus inclusion disease (MVID), a rare congenital disorder. Notably, Jaguar’s crofelemer, a plant-based prescription drug, has received Orphan Drug Designation from both the FDA and EMA for MVID and short bowel syndrome (SBS) with intestinal failure.

    Lisa Conte, President, and CEO of Jaguar Health, emphasized the company’s commitment to supporting investigator-initiated studies of crofelemer for rare diseases like MVID. These efforts aim to provide early patient access to crofelemer for debilitating conditions with limited treatment options.

    Expert Insights and Market Trends

    Dr. Mohamad Miqdady, a member of Napo’s Scientific Advisory Board, will moderate the panel discussion at the Elite Ped-GI Congress. Joining him are renowned experts, including Jaguar’s Chief Scientific Officer, Dr. Pravin Chaturvedi. The surge in trading volume, currently triple the average, underscores the market’s heightened interest in JAGX.

    Over the past month, JAGX has quadrupled in price, reflecting a trend likely to persist. As investors eagerly await updates from the Elite Ped-GI Congress, the spotlight remains on Jaguar Health, Inc. and its pioneering efforts in gastrointestinal therapeutics.

    Conclusion

    Jaguar Health, Inc.’s pre-market surge defies expectations, fueled by anticipation surrounding its participation in the Elite Ped-GI Congress. With promising developments in rare disease therapeutics, JAGX continues to capture the attention of investors, paving the way for future growth and innovation in the pharmaceutical industry.

  • Jaguar Health Inc. Rockets Upward Despite Nasdaq Listing Uncertainty

    The trading day on Friday saw Jaguar Health, Inc. (NASDAQ: JAGX) skyrocketing by an astounding 50%, followed by an additional 13% surge in after-hours trading. This unexpected surge has sparked speculation among market participants about its implications for the week ahead.

    Jaguar Health is a pharmaceutical company specializing in gastrointestinal products, operating in two segments: Human Health and Animal Health. Its flagship product, Mytesi, addresses diarrhea symptoms in adults with HIV/AIDS on antiretroviral therapy, setting it apart in the pharmaceutical industry.

    Market Dynamics and Concerns

    The surge in Jaguar Health’s stock was accompanied by an unprecedented spike in trading volume, reaching a remarkable 300 million shares traded, significantly higher than the average volume of below 13 million. This surge has raised concerns among some investors about a potential dip in profits without significant news catalysts.

    The spontaneous nature of the recent rise points a number of red flags regarding the sustainability of this jump. For this reason, many on the sidelines remain skeptical of this bullish rush.

    Delisting Update and Uncertainty

    Jaguar Health faces a delisting threat from Nasdaq due to its failure to meet the minimum bid price requirement. Although the company has requested a hearing to appeal, the outcome remains uncertain. Currently, Jaguar Health’s common stock trades under the symbol ‘JAGX,’ pending a final decision.

    Institutional Support and Long-Term Outlook

    Despite challenges, Jaguar Health has seen a steady increase in institutional holdings, indicating growing confidence among larger investors. This suggests underlying optimism regarding the company’s long-term prospects, despite market volatility.

    Conclusion

    In conclusion, while Jaguar Health’s recent stock performance has been impressive, caution is advised due to the lack of concrete news catalysts and uncertainty about its listing status.

    Nonetheless, the company’s unique product offerings and increasing institutional support provide reasons for cautious optimism amidst market turbulence. Investors should stay vigilant for developments in the coming days to gauge the stock’s trajectory.

  • Here is what you need to know about rising Jaguar Health, Inc. (JAGX) stock in Pre-Market today

    Here is what you need to know about rising Jaguar Health, Inc. (JAGX) stock in Pre-Market today

    Shares of the Jaguar Health, Inc. (JAGX) stock continued the rising trend in the pre-market trading session today on July 20, 2021. The momentum was created after the announcement of the closing of a financing of Dragon SPAC byDragon SPAC S.p.A. and Napo EU S.p.A, the Italian subsidiary of Napo Pharmaceuticals, which is a wholly-owned subsidiary of JAGX stock. Jaguar stock price saw a push of 8.28% to reach $1.57 a share at the time of this writing. The stock went high by 10.69% at the previous closing. Let’s take a closer look at recent events.

    Dragon SPAC Financing:

    The gross proceeds for the Dragon SPAC financing were totaled approximately 8,830,000 euros. This financing is the result of previously announced $10.8 million funding by the Jaguar stock into Dragon SPAC. The funds obtained from the recently registered direct offering were used in this financing. The net proceeds resulting from the private placement will be used to finance Dragon SPAC’s merger with Napo EU. Furthermore, the net proceeds would also help in financing the combined activities after the merging of Napo EU and Dragon SPAC. The merger is expected to be completed within the next three months.

    How Jaguar Health will help Napo EU:

    The Napo EU is dedicated to expanding its plant-based medicines in Europe in order to fulfill the gastrointestinal medical needs of the consumers. The JAGX stock will help Napo EU by providing the exclusive Napo license for the development and commercializing of Crofelemer in the European market.

    Completion of Phase 2 HALT-D study:

    On July 14, 2021, JAGX stock did announce the completion of the Phase 2 HALT-D study which was initiated by the third-party investigator. The study was related to the evaluation of the effectiveness of Mytesi®, a Crofelemer, against HER2-positive breast cancer patients in order to analyze the symptomatic relief in diarrhea. The Georgetown University sponsored the investigator and Genentech which is a member of Roche Group, did funding.

    JAGX annual shareholders’ meeting:

    Due to the lack of quorum, the annual shareholders’ meeting of JAGX had been adjourned for the third time and now will be held on August 6, 2021, at the San Francisco office. The record of the eligible JAGX stockholders for the annual meeting is April 12, 2021.

    Wrap Up:

    So far so good for JAGX stock as far as market sentiment is concerned. Crofelemer’s first-in-class mechanism would prove to be beneficial for the people and would make an impact in the future. Hence JAGX stock can be a good bet for investors in the long run.

  • Is JAGX Stock Up Premarket For A Reason?

    During pre-market trading on Tuesday, Jaguar Health Inc. (JAGX) climbed 2.55% to $1.61. The Jaguar Health stock finished the last trading session down -4.85% at $1.57. The price range for JAGX stock was between $1.55 and $1.65. During the past 100 days, JAGX stock traded 3.33 million shares daily but the volume of 11.44 million shares traded in the last session was much higher than that. In the past five days, JAGX shares have gained 3.29%, but have lost -17.80% over a month. We can use recent developments to provide a deeper understanding of the company as JAGX stock rose despite no current news.

    What is the latest from JAGX?

    As a commercial stage pharmaceuticals company, Jaguar Health aims to develop plant-based, non-opiod, and sustainably-derived prescription medications that are safe and effective for people and animals with GI distress, especially chronic, debilitating diarrhea. JAGX’s wholly-owned subsidiary, Napo Pharmaceuticals, Inc., is focused on the development and commercialization of plants harvested from rainforest areas for use in gastrointestinal pharmaceuticals.

    As the only oral plant-based prescription medicine approved under FDA Botanical Guidance, the Mytesi product developed by JAGX provides symptomatic relief of noninfectious diarrhea associated with HIV/AIDS in adults on antiretroviral therapy. The Napo EU S.p.A. subsidiary of Napo Pharmaceuticals aims to expand access to crofelemer in Europe.

    For the third time, Jaguar Health’s annual shareholders’ meeting on May 13 has been adjourned due to a lack of quorum.

    • Hence, the adjourned meeting of JAGX will now be held on August 6, 2021.
    • JAGX will hold its annual meeting at its San Francisco office.
    • The record date used to determine which JAGX stockholders will be eligible for the Annual Meeting was April 12, 2021.
    • The proposals have been generally well received by JAGX stockholders.
    • A JAGX stockholder who does not intend to revoke or change his or her previously delivered proxy is not required to take any action.
    • During the annual meeting, JAGX encouraged its eligible stockholders who still have not voted their shares / provided voting instructions to their broker / other record holder to do so.
    • The company counted on their participation as to reach quorum, JAGX still needs to receive votes from 2.9% of its eligible common stockholders.

    How can JAGX shareholders vote?

    There are several voting options available to Jaguar Health (JAGX) shareholders. Shareholders of JAGX can vote by internet at http://www.voteproxy.com or by phoning 800-776-9437 24 hours a day or submitting a proxy card properly executed. The street name holders of JAGX stock have the option of voting via their broker. In the process of preparing the proposals for stockholders to vote on at the Annual Meeting, JAGX has not made any changes.

  • Jaguar Health (JAGX) Closes its $6M Promissory Notes, What’s Next for JAGX Stock?

    Jaguar Health (JAGX) Closes its $6M Promissory Notes, What’s Next for JAGX Stock?

    Jaguar Health has had swift growth in 2020 as the demand for its Mytesi continues to rise.

    The pharmaceutical firm has kicked off the new year in style. Jaguar Health (JAGX) stock soared over 265% in the first week of January. The early-year gains indicate that the penny stock has a long way to go in 2021. The bull run is directing towards a positive trajectory as we move ahead.

    Recently, the company announced that it has entered into a definitive agreement to sell its promissory notes worth $6 million to Streeterville Capital—investor. Also, there’s a notable development happening across its novel proprietary drug, Crofelemer. So, 2021 is going to be exciting for Jaguar Health’s stock.

    What’s Next?

    Jaguar Health is heading in the right direction. The company has been quite active recently. On Jan. 13, 2021, Jaguar announced the purchase agreement for the sale of its common stock shares to its institutional investors. Around 4,437,870 common stock shares were floated at a per-share price of $3.38 that would bring gross proceeds of almost $15 million.

    On the very same day, the company also announced a binding agreement of terms for $6 million backed by the sale of tropical disease priority review voucher. Jaguar’s subsidiary, Napo Pharmaceuticals intends to go for an incentive for the development of Napo’s lechlemer drug with the help of this priority review voucher.

    On Jan. 19, the company signed a definitive agreement to issue and sell its secured promissory note to Streeterville for a principal amount of $6 million. Jaguar reported that the sale of Note closed on Jan. 19, 2021.

    Following the promissory note sale, Streeterville has the right to 18% of the gross proceeds of the review voucher for lechlemer drug. Whereas, Jaguar can redeem the Note at a 12.5% premium after the 6-months—any time.

    Moreover, the company is working to obtain conditional marketing authorization in Europe for its novel proprietary drug, Crofelemer. The company wants to conduct the initial study on Crofelemer in a “long-hauler” COVID-19recovery patient population in Europe. Jaguar is looking to accelerate the development and commercialization of Crofelemer as it’s the need of the hour—once it obtains the regulatory approval.

    Jaguar Health has another strong product in the market that’s making a lot of revenue. Napo’s product, Mytesi® reported a net sale of almost $2.8 million in Q3 2020, an increase from $1 million in 2019.

    Conclusion

    Jaguar Health (JAGX) is well-position across different spaces and is making way for its new product, Crofelemer, in Europe. From a penny stock in 2020 to cross the $3 price mark this year, JAGX has shown serious promise. Investors are keeping an eye on the stock; it will be making moves this year. The average trading volume stands around 57.5 million, as we write this. So, some serious bulls are coming Jaguar’s way.

  • Top key players of Biotech Industry

    Top key players of Biotech Industry

    It is evident with so many people focused on COVID-19 that biotech stocks with coronavirus vaccines and treatments have gained a lot of attention.

    The Pfizer and BioNTech vaccine is developed on mRNA science, more straightforward, quicker, and cheaper to produce than standard vaccines. Even so, amid the enormous capital and expertise of Pfizer, the large pharmaceutical firm has failed to reach the production goals it initially set for the vaccine, needing to cut the original 100 million doses in 2020 to 50 million last month.

    The development issues are not restricted to vaccines for Covid-19 either. The FDA authorized the use of antibody drugs to treat Covid-19 last month, for example, complicated to develop. Other indications include diagnostics and cell therapies are in development. Flowing are the key performers from the Biotech sectors in yesterday’s market session.

    Xenetic Biosciences Inc. (NASDAQ:XBIO) shares were trading up 193.52% at $3.17 at the time of writing on Wednesday following declaration that it saw positive data from its partner PJSC Pharmsynthez about its pivotal Phase 3 clinical study leveraging PolyXen to develop a treatment for anemia in patients with chronic kidney disease (CKD).

    Xenetic Biosciences Inc. (NASDAQ:XBIO) share price went from a low point around $0.44 to briefly over $1.85 in past 52 weeks, though shares have since pulled back to $3.17. XBIO market cap has remained high, hitting $20.45M at the time of writing, giving it price-to-sales ratio of more than 60.

    If we look at the recent analyst rating XBIO, Maxim Group initiated coverage on XBIO shares with a Buy rating.

    Moderna Inc. (MRNA) last closed at $156.59, in a 52-week range of $17.68 to $178.50. The healthcare firm recently declared that the Swiss Federal Government has increased its confirmed order commitment from 4.5 million to 7.5 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273. Analysts have a consensus price target of $122.60.

    GeoVax Labs Inc. (GOVX) stock soar by 79.06% to $5.73. The company on November 30, 2020 reported license agreement with NIH to support continued advancements in vaccine development. The most recent rating by Maxim Group, on November 19, 2020, is at a Buy.

    Intec Pharma Ltd (NASDAQ:NTEC) Shares headed rising, higher as much as 34.10% after declaring that it has entered into a feasibility agreement with GW Research Limited, London, U.K. to explore using the Accordion Pill (AP) platform for an undisclosed research program.. The most recent rating by Ladenburg Thalmann, on December 09, 2020, is at a Buy.

    Atossa Therapeutics Inc. (NASDAQ:ATOS) fall -39.03% after losing more than -$0.56 on Wednesday after the company reported pricing of $20.0 million underwritten public offering.

    Sorrento Therapeutics Inc. (SRNE) last closed at $8.21, in a 52-week range of $1.55 to $19.39. The company reported that it received US FDA clearance to proceed with Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in healthy volunteers and in newly diagnosed COVID-19 Patients.

    Greenwich LifeSciences Inc. (GLSI) stock soar by 998.35% to $57.10 after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.

    Jaguar Health Inc. (NASDAQ:JAGX) Shares headed falling, lower as much as -11.45%. The most recent rating by Rodman & Renshaw, on July 11, 2017, is at a Buy.

    Lipocine Inc. (NASDAQ:LPCN) fall -21.43% after losing more than -$0.36 on Wednesday following the announcement from the company that the U.S. Food and Drug Administration has granted tentative approval to TLANDO

    Tonix Pharmaceuticals Holding Corp. (TNXP) last closed at $0.64, in a 52-week range of $0.39 to $2.46. On December 3, 2020, the firm declared positive phase 3 RELIEF study results for TNX-102 SL 5.6 mg in Fibromyalgia.

    SELLAS Life Sciences Group Inc. (SLS) stock soar by 73.17% to $6.39. The company on December 7, 2020 revealed an exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China. The most recent rating by Oppenheimer, on November 01, 2018, is at an Outperform.

    AIkido Pharma Inc. (NASDAQ:AIKI) Shares headed rising, higher as much as 4.07% after declaring the publication of positive results from its Artificial Intelligence/Machine Learning Sponsored Research Program in the field of Pancreatic Cancer.

    Celsion Corporation (NASDAQ:CLSN) rose 12.90% after gaining more than $0.08 on Wednesday.

    ADMA Biologics Inc. (ADMA) last closed at $2.22, in a 52-week range of $1.45 to $4.65. The firm recently announced $100 million credit facility loan amendment with perceptive advisors.

    Onconova Therapeutics Inc. (ONTX) stock soar by 1.75% to $0.32. On November 23, 2020, the company reported the filing of an investigational new drug application for Multi-kinase CDK4/6 Inhibitor ON 123300. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy.